Autopsy report · NCT02365662
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Cause of deathSafety
“Safety”
Life of this trial
- Ran for about 3 years 2 months before it stopped.
- 46 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- AbbVie
- Sponsor type
- Industry
- Conditions
- Head and Neck Squamous Cell Carcinoma; Non-small Cell Lung Cancer; Triple Negative Breast Cancer; Colorectal Carcinoma; Glioblastoma Multiforme
- Interventions
- ABBV-221
- Participants
- 46
- Sites
- 5
- Countries
- Spain, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.